Publications by authors named "Garth D Nelson"

Claim this Profile
N
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma.
Tina J Hieken, David Zahrieh, Thomas J Flotte, Roxana S Dronca, Evidio Domingo-Musibay, Garth D Nelson

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.
Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang

J Immunother Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Helen J Ross, David Kozono, Xiaofei F Wang, James John Urbanic, Terence M Williams, Garth D Nelson

JAMA Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence.
Frank A Sinicrope, Garth D Nelson, Bahar Saberzadeh-Ardestani, Diana I Segovia, Rondell P Graham

Cancer Res Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Tina J Hieken, Garth D Nelson, Thomas J Flotte, Eric P Grewal, Jun Chen

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative Treatment of Locally Advanced Rectal Cancer.
Deborah Schrag, Qian Shi, Martin R Weiser, Marc J Gollub, Leonard B Saltz, Garth D Nelson

N Engl J Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
Ethan Basch, Amylou C Dueck, Lauren J Rogak, Sandra A Mitchell, Lori M Minasian, Garth D Nelson

J Clin Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.
Amanda I Phipps, Qian Shi, Paul J Limburg, Garth D Nelson, Daniel J Sargent

Int J Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).
Frank A Sinicrope, Michelle R Mahoney, Harry H Yoon, Thomas C Smyrk, Stephen N Thibodeau, Garth D Nelson

Clin Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Grzegorz S Nowakowski, Betsy LaPlant, William R Macon, Craig B Reeder, James M Foran, Garth D Nelson

J Clin Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Julian R Molina, Nathan R Foster, Thanyanan Reungwetwattana, Garth D Nelson, Andrew V Grainger

Lung Cancer· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, Garth D Nelson, Steven R Alberts

J Natl Cancer Inst· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Jocelin Huang, Suresh G Nair, Michelle R Mahoney, Garth D Nelson, Anthony F Shields

Clin Colorectal Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Harry H Yoon, David Tougeron, Qian Shi, Steven R Alberts, Michelle R Mahoney, Garth D Nelson

Clin Cancer Res· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Frank A Sinicrope, Michelle R Mahoney, Thomas C Smyrk, Stephen N Thibodeau, Robert S Warren, Garth D Nelson

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current use and surgical efficacy of laparoscopic colectomy in colon cancer.
Robert P Sticca, Steven R Alberts, Michelle R Mahoney, Daniel J Sargent, Lisa M Finstuen, Garth D Nelson

J Am Coll Surg· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.
Amanda I Phipps, Qian Shi, Polly A Newcomb, Garth D Nelson, Daniel J Sargent

J Clin Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Grace K Dy, Sumithra J Mandrekar, Garth D Nelson, Jeffrey P Meyers, Araba A Adjei

J Thorac Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Jan Franko, Qian Shi, Charles D Goldman, Barbara A Pockaj, Garth D Nelson

J Clin Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423.
Cheng E Chee, James R Jett, Albert M Bernath, Nathan R Foster, Garth D Nelson

Cancer· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials.
Nathan R Foster, Sumithra J Mandrekar, Steven E Schild, Garth D Nelson, Kendrith M Rowland

Cancer· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis